Current interventional strategy for the treatment of hepatic alveolar echinococcosis.
Fiche publication
Date publication
décembre 2016
Journal
Expert review of anti-infective therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BLAGOSKLONOV Oleg, Dr VUITTON Lucine
Tous les auteurs :
Vuitton DA, Azizi A, Richou C, Vuitton L, Blagosklonov O, Delabrousse E, Mantion GA, Bresson-Hadni S
Lien Pubmed
Résumé
The use of various types of invasive interventions combined with anti-infective drugs in the therapeutic strategy of alveolar echinococcosis (AE) has changed during the last 30 years. Areas covered: This article reviews the current respective indications of surgical, percutaneous and perendoscopic interventions in AE and proposes an integrative therapeutic strategy. Expert commentary: Hepatic resection is indicated whenever it is feasible and curative; palliative surgery should be avoided; percutaneous procedures are best adapted to the drainage of the necrotic cavity present in advanced cases; perendoscopic procedures with stenting are best adapted to alleviating the biliary complications that are common and life-threatening in AE patients. Continuous administration of albendazole or mebendazole, without interruption is mandatory in all cases, temporarily (recommended duration: 2 years) after radical lesion resection in patients without immune suppression; for life in all other cases. Long-term follow-up is essential.
Référence
Expert Rev Anti Infect Ther. 2016 Dec;14(12):1179-1194